Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTarsus Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.73 | -$0.66 | -$0.70 |
| Q2 2025 | 1 | -$0.62 | -$0.58 | -$0.59 |
| Q3 2025 | 1 | -$0.60 | -$0.56 | -$0.58 |
| Q4 2025 | 1 | -$0.16 | -$0.15 | -$0.15 |
| Q1 2026 | 1 | $0.40 | $0.43 | $0.41 |
| Q2 2026 | 1 | $0.60 | $0.64 | $0.61 |
| Q3 2026 | 1 | $0.79 | $0.84 | $0.80 |
| Q4 2026 | 1 | $1.07 | $1.15 | $1.10 |
Tarsus Pharmaceuticals, Inc. Earnings Date And Information
Tarsus Pharmaceuticals, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.61 earnings per share for the quarter, topping analysts' consensus estimates of $-0.9 by $0.29. The company had revenue of 48.12 M for the quarter and had revenue of 17.45 M for the year. Tarsus Pharmaceuticals, Inc. has generated $-5 earnings per share over the last year ($-4.62 diluted earnings per share) and currently has a price-to-earnings ratio of -14.13. Tarsus Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Tarsus Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.90 | -$0.61 | 0.29 | $43.18 M | $48.12 M |
| 08/08/2024 | Q2 2024 | -$0.98 | -$0.88 | 0.1 | $32.33 M | $40.81 M |
| 05/08/2024 | Q1 2024 | -$1.15 | -$1.01 | 0.14 | $27.61 M | |
| 02/27/2024 | Q4 2023 | -$1.37 | -$1.31 | 0.06 | $13.08 M | |
| 11/09/2023 | Q3 2023 | -$1.40 | -$1.28 | 0.12 | $399,560 | $1.87 M |
| 08/10/2023 | Q2 2023 | -$1.08 | -$1.17 | -0.09 | $15.28 M | |
| 05/09/2023 | Q1 2023 | -$0.95 | -$0.82 | 0.13 | $2.50 M | |
| 03/16/2023 | Q4 2022 | -$0.49 | $10.00 M | |||
| 11/09/2022 | Q3 2022 | -$0.98 | -$0.84 | 0.14 | $3.50 M | $0 |
| 08/11/2022 | Q2 2022 | -$0.65 | -$0.26 | 0.39 | $11.25 M | $15.28 M |
| 05/11/2022 | Q1 2022 | -$0.98 | $539,000 | |||
| 03/14/2022 | Q4 2021 | -$0.77 | -$0.72 | 0.05 | $338,000 | |
| 11/10/2021 | Q3 2021 | -$0.76 | $5.33 M | $1.24 M | ||
| 08/04/2021 | Q2 2021 | $0.31 | $4.53 M | $22.02 M | ||
| 05/11/2021 | Q1 2021 | -$0.64 | $0.51 | 1.15 | $33.43 M | |
| 03/31/2021 | Q4 2020 | -$0.66 | -$0.56 | 0.1 | $0 | |
| 11/24/2020 | Q3 2020 | -$0.54 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.30 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.18 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.13 | $0 |
Tarsus Pharmaceuticals, Inc. Earnings: FAQ's
When is Tarsus Pharmaceuticals, Inc.'s earnings date?
Tarsus Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
Did Tarsus Pharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Tarsus Pharmaceuticals, Inc. (:TARS) reported $-0.61 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.9 by $0.29.
How can I listen to Tarsus Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Tarsus Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much revenue does Tarsus Pharmaceuticals, Inc. generate each year?
Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded annual revenue of $17.45 M.
How much profit does Tarsus Pharmaceuticals, Inc. generate each year?
Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded net income of $17.45 M. Tarsus Pharmaceuticals, Inc. has generated $-4.62 earnings per share over the last four quarters.
What is Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio?
Tarsus Pharmaceuticals, Inc. (:TARS) has a price-to-earnings ratio of -14.13 and price/earnings-to-growth ratio is -0.94.